Glucagon Receptor Antagonists Sulfonate Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current glucagon receptor antagonists face challenges in achieving optimal therapeutic efficacy due to limitations in receptor binding affinity, oral bioavailability, and stability, which are crucial for effectively managing glucoregulatory and glucagon receptor-mediated diseases.
Innovation Solution
Development of enantiomerically pure and substantially enantiomerically pure compounds, including polymorphs, crystal forms, pharmaceutically acceptable salts, co-crystals, and prodrugs, which exhibit improved receptor binding properties and oral bioavailability, thereby enhancing their suitability as therapeutic agents for glucagon receptor-mediated conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If carboxylic acid-based glucagon receptor antagonists are used to achieve high binding affinity, then receptor binding properties are improved, but chemical and physical properties differ from sulfonate compounds leading to limitations in oral bioavailability and stability
Solution Approach 1:
The patent applies parameter changes by systematically modifying the chemical structure of glucagon receptor antagonists, specifically transitioning from carboxylic acid to sulfonate groups and varying R-groups at different positions. This structural parameter modification enables optimization of both receptor binding affinity and oral bioavailability, resolving the contradiction between these two properties.
Solution Approach 2:
The patent employs composite material principles by creating hybrid molecular structures that combine the high binding affinity characteristics of carboxylic acid-based antagonists with the improved oral bioavailability and stability of sulfonate compounds. The resulting compounds integrate beneficial properties from both chemical classes to achieve superior overall performance.
2Reliability
If glucagon receptor antagonists are designed for high potency, then therapeutic efficacy is improved, but complexity of molecular structure increases affecting manufacturing and formulation
Solution Approach 1:
The patent applies segmentation by dividing the molecular structure into distinct functional modules: a core scaffold, variable R-groups at specific positions, and substituent groups. This modular approach allows systematic optimization of potency while maintaining manufacturability, as each segment can be independently designed and synthesized.
Solution Approach 2:
The patent uses parameter changes by systematically varying molecular weight, hydrophobicity, and functional group composition to achieve high therapeutic efficacy. By controlling these parameters within specific ranges, the patent maintains potency while avoiding excessive molecular complexity that would hinder manufacturing.
3Reliability
If enantiomerically pure compounds are synthesized to improve receptor binding properties, then binding affinity is enhanced, but manufacturing complexity and cost increase
Solution Approach 1:
The patent applies preliminary action by incorporating chiral centers and stereoselective elements into the molecular design from the outset. This allows for enantioselective synthesis using chiral catalysts or auxiliaries in early synthetic steps, rather than requiring complex resolution processes later, thereby reducing overall manufacturing complexity while maintaining high binding affinity.
Data Source
AI summary
Provided herein are solid state forms of compounds, including enantiomerically pure forms thereof, and pharmaceutically acceptable salts or co-crystals and prodrugs thereof which have glucagon receptor antagonist or inverse agonist activity. Further, provided herein are pharmaceutical compositions and methods of treating, preventing, ameliorating, delaying the time to onset or reducing the risk for the development or progression of at least one condition, disease, or disorder for which one or more glucagon receptor antagonist is indicated, including Type I and II diabetes, insulin resistance, hyperglycemia, ketoacidosis, or ketosis.